Guido Gerken

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen et al. · The Lancet Oncology · 2019 · 1.6K citations

Oncology, Hepatology, α-Fetoprotein Concentrations +10

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

Harry L.A. Janssen, Monika van Zonneveld, Hakan Şentürk et al. · The Lancet · 2005 · 1.2K citations

Hepatology, Interferon Alfa-2b Alone, Viral Hepatitis +6

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

Jordi Bruix, Jean‐Luc Raoul, Morris Sherman et al. · Journal of Hepatology · 2012 · 819 citations · Full text

Toll-Like Receptor 2 Controls Mucosal Inflammation by Regulating Epithelial Barrier Function

Elke Cario, Guido Gerken, Daniel K. Podolsky · Gastroenterology · 2007 · 673 citations

Inflammation, Toll-like Receptors, Controls Mucosal Inflammation +12

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath et al. · The Lancet Oncology · 2012 · 549 citations

Second-line Treatment, Placebo-controlled Phase 2, Oncology +11